12-month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry.

Mateusz NiedzwieckiAdrian Robert HuntVuong NguyenHemal MehtaCatherine Creuzot-GarcherPierre Henri GabrielleMartin GuilleminSamantha Fraser-BellJennifer ArnoldIan L McAllisterMark GilliesDaniel Barthelmes

Published in: Acta ophthalmologica (2021)

Both aflibercept and ranibizumab improved VA and reduced CST in eyes with CRVO in routine clinical practice, with aflibercept showing significantly greater improvements in this comparative analysis.

Keyphrases

age related macular degeneration
clinical practice
optical coherence tomography
diabetic retinopathy
electronic health record
big data
type diabetes
skeletal muscle
machine learning
metabolic syndrome
insulin resistance